Exenatide
Exenatide is a synthetic version of exendin-4, originally isolated by John Eng at the Bronx VA Medical Center in 1992 from the saliva of the Gila monster (Heloderma suspectum).[3] The peptide is only 53% homologous to native human GLP-1 but is naturally resistant to DPP-4 — that natural resistance is what made it the first clinically usable incretin mimetic, validating the GLP-1 receptor as a therapeutic target and opening the path to all subsequent agents in the class.
In contrast to the long-acting weekly agents that followed, exenatide carries a heavier GI side-effect burden (especially Byetta BID) and is associated with anti-exenatide antibody formation in a substantial minority of users — antibodies that can reduce efficacy.[1] Twice-daily Byetta was discontinued in the United States in 2024.[citation needed] Bydureon BCise remains available but is no longer commonly prescribed first-line.Experience
Log in to add your own experience.
Problems
Titration strategies
Steady-state plasma exenatide is reached only after 6–7 weeks of dosing — counsel patients that the medicine will keep ramping up well after the first injection. HbA1c response should be assessed at 12+ weeks, not earlier.[2]
Renal dosing: avoid if CrCl <45 mL/min.[2]Effects
- Nausea — historically the highest of any GLP-1 RA. ~40–50% of Byetta BID users report nausea; ~20% with Bydureon weekly.[1][2]
- Vomiting, diarrhea, constipation, dyspepsia[1]
- Injection-site reactions — notably higher with Bydureon (small nodules at injection sites are common, often visible/palpable for weeks)[2]
- Anti-exenatide antibodies — form in ~40% of users; high titers correlate with reduced glycemic efficacy[1]
- Headache, jitteriness (less common)[citation needed]
Pharmacokinetics
Chemistry. Exendin-4 — a 39-amino-acid peptide originally isolated from the saliva of the Gila monster (Heloderma suspectum). Only 53% homologous with human GLP-1 but naturally resistant to DPP-4 cleavage because of a glycine at position 2.[3]
Byetta (BID): rapid absorption, peak ~2.1 h, half-life ~2.4 h. Renal elimination predominates (unlike most other GLP-1 RAs); dose adjustment required for CrCl 30–50, contraindicated <30.[1]
Bydureon BCise (weekly): exenatide is encapsulated in slow-release biodegradable polymer microspheres; multiple peaks occur as successive microsphere cohorts release the peptide. Steady-state plasma levels are reached only after 6–7 weeks of weekly dosing — meaning early efficacy looks weaker than other weekly GLP-1 RAs.[2]Pharmacodynamics
Receptor pharmacology. Selective agonist of the GLP-1 receptor. Mechanism identical to other GLP-1 RAs (glucose-dependent insulin secretion, glucagon suppression, delayed gastric emptying, hypothalamic appetite suppression).[4]
At maintenance doses:
- HbA1c reduction of ~0.8–1.0 percentage points (Byetta 10 µg BID or Bydureon 2 mg/wk)[1][2]
- Weight loss of ~2–3 kg[1]
- Cardiovascular outcomes: non-inferior but not superior to placebo in T2DM (EXSCEL) — the only major GLP-1 RA CVOT not to demonstrate superiority[5]
Interactions
Pregnancy and lactation
Monitoring
- Baseline: HbA1c, weight, BP, renal function (especially important for exenatide — renally cleared)[1]
- Personal or family history of MTC or MEN2 — contraindicated, do not start (Bydureon only — Byetta's label predates the class boxed warning conversion)[2]
- Every 3 months for first year: HbA1c, weight, GI tolerability, renal function, signs of pancreatitis or gallbladder disease
- Pre-procedure: Byetta — skip the dose before the procedure; Bydureon — hold weekly dose ≥7 days pre-op[6]
Patient counseling
- Byetta: inject within 60 min before a meal (not after). Skip the dose if you skip the meal.[1]
- Bydureon: same day each week. Suspension must be activated by vigorous shaking until uniformly cloudy — administration immediately after mixing is required.[2]
- Expect small injection-site nodules with Bydureon — these are the polymer microspheres and usually resolve over weeks to months.[2]
- GI side effects with Byetta BID peak in the first 8 weeks and often improve.[1]
- Surgery: hold Bydureon ≥7 days pre-op; for Byetta, skip the pre-procedure dose.[6]
Relevant anecdote
0
Relevant Literature
No literature entries yet.
Log in to submit relevant literature.
See also
References
- ↑ 1.00 1.01 1.02 1.03 1.04 1.05 1.06 1.07 1.08 1.09 1.10 1.11 1.12 1.13 1.14 1.15 1.16 1.17 1.18 1.19 1.20 1.21 US FDA. Byetta (exenatide) prescribing information. AstraZeneca. https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021773s9s11s18s22s25lbl.pdf
- ↑ 2.00 2.01 2.02 2.03 2.04 2.05 2.06 2.07 2.08 2.09 2.10 2.11 2.12 2.13 2.14 2.15 2.16 2.17 US FDA. Bydureon BCise (exenatide extended-release) prescribing information. AstraZeneca. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209210s000lbl.pdf
- ↑ 3.0 3.1 Eng J, Kleinman WA, Singh L et al. (1992). Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. J Biol Chem 267(11):7402–5.
- ↑ Drucker DJ (2022). GLP-1 physiology informs the pharmacotherapy of obesity. Mol Metab 57:101351.
- ↑ Holman RR, Bethel MA, Mentz RJ et al. (2017). Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes (EXSCEL). NEJM 377(13):1228–39. doi:10.1056/NEJMoa1612917
- ↑ 6.0 6.1 Kindel TL et al. (2024). Perioperative GLP-1 receptor agonist safety guidance. Surg Obes Relat Dis 20(12):1183–8.